S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
New CBOE “special perk” helps traders target income every weekend (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

Coherus BioSciences Stock Price, News & Analysis (NASDAQ:CHRS)

$2.30
0.00 (0.00%)
(As of 12/4/2023 ET)
Compare
Today's Range
$2.21
$2.37
50-Day Range
$1.59
$3.98
52-Week Range
$1.43
$10.99
Volume
2.84 million shs
Average Volume
2.80 million shs
Market Capitalization
$256.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.89

Coherus BioSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
416.9% Upside
$11.89 Price Target
Short Interest
Bearish
19.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.08mentions of Coherus BioSciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$450,662 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.17) to ($0.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

128th out of 952 stocks

Biotechnology Industry

3rd out of 33 stocks


CHRS stock logo

About Coherus BioSciences Stock (NASDAQ:CHRS)

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Stock Price History

CHRS Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
What 6 Analyst Ratings Have To Say About Coherus BioSciences
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Coherus BioSciences Inc CHRS
Why Coherus BioSciences Was Plummeting This Week
Coherus BioSciences Shares Hit All-Time Low
EH, HOWL and TNON among pre-market losers
Coherus stock falls after guidance cut
Coherus BioSciences's Earnings: A Preview
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/04/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
299
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$11.89
High Stock Price Target
$23.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+416.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-291,750,000.00
Net Margins
-102.86%
Pretax Margin
-103.04%

Debt

Sales & Book Value

Annual Sales
$211.04 million
Book Value
($1.77) per share

Miscellaneous

Free Float
99,125,000
Market Cap
$256.13 million
Optionable
Optionable
Beta
0.68

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Dennis M. LanfearMr. Dennis M. Lanfear (Age 68)
    Chairman, President & CEO
    Comp: $1.79M
  • Mr. McDavid StilwellMr. McDavid Stilwell (Age 51)
    Chief Financial Officer
    Comp: $719.64k
  • Mr. Bryan J. Mcmichael (Age 45)
    Senior VP of Accounting, Principal Accounting Officer & Corporate Controller
  • Mr. Richard L. Hameister
    Chief Technical Officer
  • Mr. Marek Ciszewski J.D.
    Senior Vice President of Investor Relations
  • Cheston Turbyfill
    Vice President of Communications
  • Ms. Rebecca Sunshine (Age 60)
    Chief Human Resources Officer
  • Mr. Michael Chen
    Senior Vice President of Commercial Analytics & Trade
  • Mr. Paul Reider (Age 54)
    Chief Commercial Officer
  • Dr. Theresa M. Lavallee Ph.D. (Age 57)
    Chief Development Officer & Chairman of Scientific Advisory Board














CHRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price target for 2024?

7 equities research analysts have issued 1 year target prices for Coherus BioSciences' stock. Their CHRS share price targets range from $6.00 to $23.00. On average, they expect the company's share price to reach $11.89 in the next twelve months. This suggests a possible upside of 416.9% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2023?

Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS stock has decreased by 71.0% and is now trading at $2.30.
View the best growth stocks for 2023 here
.

Are investors shorting Coherus BioSciences?

Coherus BioSciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 21,690,000 shares, an increase of 9.3% from the October 31st total of 19,840,000 shares. Based on an average daily volume of 4,280,000 shares, the short-interest ratio is currently 5.1 days.
View Coherus BioSciences' Short Interest
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. The biotechnology company earned $74.57 million during the quarter, compared to the consensus estimate of $80.13 million.

What ETFs hold Coherus BioSciences' stock?

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR).

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Barclays PLC (2.51%), Peregrine Capital Management LLC (1.46%), Northern Trust Corp (0.86%), Rafferty Asset Management LLC (0.79%), Sei Investments Co. (0.75%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
This page (NASDAQ:CHRS) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -